Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material

Phase 4

Completed

Conditions: Radiocontrast-induced Nephropathy

Interventions: Drug: Acetylcysteine
Drug: Visipaque 320

First Posted Date: 2007-11-14

Last Posted Date: 2015-06-08

Lead Sponsor: University of Edinburgh

Target Recruit Count: 90

Registration Number: NCT00558142

Locations: 🇬🇧
Clinical Research Facility, Royal Infirmary Edinburgh, Edinburgh, Midlothian, United Kingdom

Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy

Phase 2

Completed

Conditions: Diabetic Nephropathy
Chronic Kidney Disease
Diabetes Type 2

Interventions: Drug: N-acetylcysteine

First Posted Date: 2007-11-12

Last Posted Date: 2007-11-12

Lead Sponsor: Shiraz University of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT00556465

Locations: 🇮🇷
Mohammad mahdi sagheb, Shiraz, Fars, Iran, Islamic Republic of

An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents

Phase 1

Completed

Conditions: Cannabis Dependence

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2007-10-11

Last Posted Date: 2018-05-23

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 24

Registration Number: NCT00542750

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder

Phase 2

Terminated

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: placebo
Drug: N-Acetylcysteine

First Posted Date: 2007-10-04

Last Posted Date: 2020-04-02

Lead Sponsor: Yale University

Target Recruit Count: 10

Registration Number: NCT00539513

N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD

Phase 2

Terminated

Conditions: Self-Injurious Behavior
Borderline Personality Disorder

Interventions: Drug: placebo
Drug: N-Acetylcysteine

First Posted Date: 2007-10-04

Last Posted Date: 2020-04-15

Lead Sponsor: Yale University

Target Recruit Count: 6

Registration Number: NCT00539188

Locations: 🇺🇸
Yale OCD Research Clinic, New Haven, Connecticut, United States

N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure

Phase 2

Conditions: Heart Failure, Congestive
Kidney Failure, Chronic

Interventions: Drug: N-acetylcysteine

First Posted Date: 2007-09-20

Last Posted Date: 2007-09-20

Lead Sponsor: Bayside Health

Target Recruit Count: 10

Registration Number: NCT00532688

Locations: 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia

Efficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis

Phase 4

Completed

Conditions: Otosclerosis

Interventions: Drug: Placebo (NaCl)
Drug: Acetylcysteine

First Posted Date: 2007-09-06

Last Posted Date: 2013-09-11

Lead Sponsor: Karolinska University Hospital

Target Recruit Count: 152

Registration Number: NCT00525551

Locations: 🇸🇪
Karolinska University Hospital Huddinge, Huddinge, Sweden
🇸🇪
Karolinska University Hospital, Dept. of Otorhinolaryngology, Stockholm, Sweden
🇸🇪
Academic Hospital, Uppsala, Sweden

Influence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer

Phase 4

Completed

Conditions: Pulmonary Morbidity

Interventions: Drug: 250mL glucose 5%
Drug: n-acetylcysteine

First Posted Date: 2007-08-07

Last Posted Date: 2013-08-28

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 29

Registration Number: NCT00512265

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland
🇨🇭
Department of Surgery, Triemli Hospital, Zurich, Switzerland, Zurich, Switzerland

Effect of N-Acetylcysteine (NAC) on Creatinine in Chronic Kidney Disease

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: N-acetylcysteine

First Posted Date: 2007-07-25

Last Posted Date: 2009-04-15

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 60

Registration Number: NCT00506506

Locations: 🇨🇦
London Health Sciences Centre, London, Ontario, Canada

Effect of N-Acetylcysteine on Residual Renal Function in Chronic Hemodialysis Patients

Not Applicable

Conditions: Hemodialysis
Renal Failure

First Posted Date: 2007-07-25

Last Posted Date: 2007-07-25

Lead Sponsor: Assaf-Harofeh Medical Center

Registration Number: NCT00507052

Locations: 🇮🇱
Assaf Harofeh, Zerifin, Israel

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy